



## **Immunity at the Gate of Entrance; Vaccines against Respiratory Viruses such as Influenza, Corona, and RSV 2.0**

Guest Editor:

**Dr. Jorgen De Jonge**

Department for Immune  
Mechanisms, Centre for  
Infectious Disease Control,  
National Institute of Public  
Health and the Environment  
(RIVM), Bilthoven, The  
Netherlands

Deadline for manuscript  
submissions:

**closed (15 October 2021)**

### **Message from the Guest Editor**

Most vaccines induce systemic immunity through intramuscular administration. This route of vaccination disregards a very potent part of the immune system—local adaptive immunity.

Challenges include adjuvation, formulation, and induction of long-lasting immunity. For influenza (and possibly SARS-CoV-2) in particular, a broadly reactive immunity is a challenge, and Trm and local stem antibodies may be an answer. For corona, RSV, and influenza immunity, longevity is a holy grail. Therefore, research that provides insight into local immune parameters that correlate with protection against respiratory viruses or that are shown to be long-lasting is welcomed. Immune induction may be through vaccination, using adjuvants and formulation techniques to steer the immune response or by immune transfer techniques, etc. when this leads to a better understanding of potent vaccine targets.

Combining insights and strategies developed for different respiratory viruses into one Special Issue encourages cross-pollination of the different research fields and would advance the development of locally administered respiratory vaccines overall.

Dr. Jorgen De Jonge  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)